Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, speaks about details in the trends in lung cancer demographics and changes in histology by race and gender.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, details the trends in lung cancer demographics and changes in histology by race and gender.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the demographics and epidemiology of lung cancer.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, describes the types of situations in which local therapy is appropriate for treating limited acquired resistance.
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, evaluates a variety of particular systemic treatment agents for possible use in elderly patients.
Drs. Leora Horn, Ben Solomon, & Jack West consider whether third generation EGFR TKIs, so active in patients with acquired resistance, might be best used prior to development of acquired resistance.
“Gratitude is one of the most medicinal emotions we can feel.” (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.
“Gratitude is one of the most medicinal emotions we can feel.” (Sara Avant Stover) Thank you for joining GRACE in our #LCAM15 activities.
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.
Dr. Jack West reviews the Lung Cancer Master Protocol for second line treatment of patients with advanced squamous NSCLC, an "umbrella protocol" in which all patients undergo molecular testing and have treatment assigned by the results.
I was reading the article by Dr West, How long should we continue immune checkpoint inhibitor therapy in patients who respond? This was written in...
Dr. West or other oncologist: I am a 60 yo, post-14 yr stage 2 breast cancer patient. I went to my oncologist in March with a complaint of an off and...
Please I would like someone could please interpret this part of the PET/SCAN for me. Development of a small hypermetabolic focus within the T6...
Hoping I may get some answers as it seems everything we try is failing for one reason or another. Stage 4 ROS1 diagnosed Feb 2018 with BM’s treated...
Well, here we are, barring any last minute complications my wife should start the TAK-788 trial next week. She has already had her main blood work and...
Lung cancer patients with high MET amplification appear to do well on Xalkori (crizotinib), a drug that is approved for ALK positive patients.
[powerpress]
Lung cancer patients with the EGFR mutation who had progressed on other drugs did well on a new drug in clinical trial, though one particular side effect concerns some.
[powerpress]
EGFR positive lung cancer patients who had seen cancer progression responded well to a new drug in an early clinical trial.
[powerpress]
It's been a decade since EGFR gene mutations were first identified as highly correlated with a high probability of response to EGFR tyrosine kinase inhibitors (TKIs) like Iressa (gefitinib) and Tarceva (erlotinib), and more recently Gilotrif (afatinib).
An analysis of two large studies of EGFR lung cancer patients tried to determine if Gilotrif helped patients live longer.
[powerpress]
One of the high profile presentations in the lung cancer track at ASCO 2014 was from Dr. James Yang of a pooled analysis of the LUX-Lung 3 and LUX-Lung 6 trials, each comparing Gilotrif (afatinib) to standard chemotherapy as first line treatment of EGFR mutation-positive advanced NSCLC, which for the first time demonstrated an actual survival benefit not seen in similarly designed trials with Iressa (gefitinib) or Tarceva (erlotinib).
Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?
[powerpress]
Drs. Nasser Hanna, Melissa Johnson and Jack West discuss results of a phase 2 trial presented at ASCO 2014 that studied if adding Avastin (bevicizumab) to Tarceva helped EGFR positive lung cancer patients increase progression-free survival. June 2014.
[powerpress]
Dr. Joel Neal of Stanford University Medical Center talks about FGFR - fibroblast growth factor receptor - and how it can impact non-small cell lung cancer growth.
[powerpress]
I recently had the honor of providing the expert commentary at the ASCO 2014 conference on three high impact lung cancer presentations, all on the subject of treatment options for molecularly defined populations (EGFR and ALK). I'll review the findings from these three abstracts and my perspective on each of these, starting with a very provocative presentation by Dr.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.